Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements review identified that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide a... https://richardy850iff4.ltfblog.com/profile